ArticleThrombosis journal2025
Non-invasive dentistry method for clinical determination of bleeding time: evaluation in subjects with and without direct oral anticoagulant therapy.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessing bleeding duration in patients on direct oral anticoagulants (DOACs) is crucial for evaluating reversal strategies, yet no standardized methods are currently available for clinical trials. We investigated a non-invasive, reproducible bleeding model based on a routine dental cleaning procedure, aiming to provide a clinically meaningful endpoint for testing DOAC antidots. We enrolled 90 subjects in this prospective observational pilot study: 49 not receiving DOACs (group 1; 30 female, 19 male; mean age: 40.7 ± 16 years) and 41 on DOACs (group 2; 22 female, 19 male; mean age: 71.3 ± 20.4 years). Mouth-rinse samples were collected before and at 5-minute intervals for up to 60 min following bleeding-on-probing assessment, periodontal staging, and dental cleaning. Red blood cell (RBC) counts in these samples were determined using a hemocytometer. Bleeding cessation was defined as an RBC count below 150 cells/µL. Reaching this threshold within 15 min was defined as the clinical endpoint (EP). In group 1, 83.7% reached the EP (group 1a (without gingivitis): 90.9%; group 1b (with gingivitis): 77.8%). In group 2, only 39% reached the EP (group 2a (without gingivitis): 60%; group 2b (with gingivitis): 32.3%; p < 0.001 vs. group 1). The most relevant comparison for future antidote trials is between group 1b (non-DOAC with gingivitis) and group 2b (DOAC with gingivitis; p < 0.001). This model offers a standardized, non-invasive, and clinically relevant approach to monitor bleeding in DOAC-treated patients. The defined clinical endpoint (≤ 150 RBC/µL after 15 min) could serve as a useful surrogate for evaluating the efficacy of temporary DOAC reversal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.